Cancer Antigen 19-9 (CA 19-9)

Catalogue Number: 151-99
Product Name Cancer Antigen 19-9
Source Human Liver Metastases
Catalogue Number 151-99
Purity Highly Purified
Form Liquid
Activity Typically > 500 kU/mL (Roche Elecsys EIA)
Purity Note High purity, low cross contamination of other cancer antigens
Purification Gel filtration & ion-exchange chromatography
Formulation Solution in phosphate buffered saline, pH 7.4 with sucrose and 0.05% sodium azide.
Appearance Clear and Colorless
Pairing Information Capture Ab: 151-91 - anti-Human CA 19-9 Monoclonal Antibody
Detection Ab: 151-92 - anti-Human CA 19-9 Monoclonal Antibody
Antigen: 151-99 - CA 19-9 from human metastatic liver
Storage -20°C
Recertification 3 years
Related Products 151-25 - CA-125 antigen from human ascites fluid
151-53 - CA 15-3 antigen from human ascites fluid
151-10 - CEA antigen from human liver
Infectious Disease Testing Negative or non-reactive at the donor level for anti-HIV 1 and 2, anti-HCV and HBsAg by FDA approved methods.
Synonyms Tumor Marker 19-9, CA 19-9, Cancer Antigen 19-9, carbohydrate antigen 19-9, Sialylated Lewis (a) Antigen
Product Specificity Gastrointestinal, Pancreatic Cancer

Lee Biosolutions the leading producer and supplier of Cancer Antigen 19-9 (CA 19-9) for pancreatic management research and biomarker for manufacturing.

Custom preparations, technical support, bulk quantities and aliquoting available, email for more details.

Cancer Antigen 19-9 is a tumor marker elevated in blood of patients with carcinoma of the gastro-intestinal tract. Primarily used distinguishing pancreatic cancer from pancreatitis, CA 19-9 is not sufficiently specific for use as a cancer screening test. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97% for tumor presence. CA 19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma.

A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease.

Add to Cart
151-99-25 $ 310.00 25 kU
151-99-100 $ 999.00 100 kU
151-99-1,000 Inquire 1,000 kU